Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade B 23.22 -4.37% -1.06
EXEL closed down 4.37 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical EXEL trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 MACD Bearish Signal Line Cross Bearish 0.00%
Mar 19 1,2,3 Pullback Bullish Bullish Swing Setup -4.52%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.52%
Mar 19 Upper Bollinger Band Walk Strength -4.52%
Mar 19 Inside Day Range Contraction -4.52%
Mar 18 New 52 Week High Strength -3.81%
Mar 18 Upper Bollinger Band Walk Strength -3.81%
Mar 18 Outside Day Range Expansion -3.81%
Mar 18 Overbought Stochastic Strength -3.81%

Older signals for EXEL ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Genentech Protein Kinase Inhibitor Metastatic Castration Resistant Prostate Cancer Small Molecule Therapies
Is EXEL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 25.31
52 Week Low 13.42
Average Volume 3,818,964
200-Day Moving Average 19.9256
50-Day Moving Average 22.889
20-Day Moving Average 23.4415
10-Day Moving Average 24.147
Average True Range 0.8177
ADX 29.7
+DI 22.0206
-DI 17.2237
Chandelier Exit (Long, 3 ATRs ) 22.8569
Chandelier Exit (Short, 3 ATRs ) 23.5131
Upper Bollinger Band 25.0588
Lower Bollinger Band 21.8242
Percent B (%b) 0.43
BandWidth 13.798605
MACD Line 0.5017
MACD Signal Line 0.5135
MACD Histogram -0.0118
Fundamentals Value
Market Cap 6.83 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 116.10
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.96
Resistance 3 (R3) 25.15 24.77 24.67
Resistance 2 (R2) 24.77 24.32 24.67 24.57
Resistance 1 (R1) 23.99 24.05 23.80 23.80 24.48
Pivot Point 23.61 23.61 23.51 23.51 23.61
Support 1 (S1) 22.83 23.16 22.64 22.64 21.96
Support 2 (S2) 22.45 22.89 22.35 21.87
Support 3 (S3) 21.67 22.45 21.77
Support 4 (S4) 21.48